Guy Archibald Innes bought $15k of VNRX
director at VOLITIONRX LTD. 20,000 shares at an average of $0.77, traded Nov 27, 2023, filed Nov 28, 2023.
Score components
- +15RoleDirector
- 0Trade size$15k at market
- 0Relative to holdingsHoldings up 3.3%
- +8Price context71% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- -5Track recordMedian 6-month excess return -66% over 5 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.4%, 3m +26.9%, 6m -12.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001477932-23-008822, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 27, 2023 | POpen-market purchase Common Stock | +20,000 | $0.77 | $15k | 627,161 | Nov 28, 2023 |
Related signals
Other insiders at VOLITIONRX LTD and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | VNRXbuy VOLITIONRX LTD | Cameron John Reynolds President and CEO | $7,000 20,000 shares | +1% | |
| 63Notable | VOLITIONRX LTD | Guy Archibald Innes director | $49k 96,153 shares | +10% | |
| 70Notable | VOLITIONRX LTD | Cameron John Reynolds President and CEO | $56k 110,000 shares | +5% | |
| 48Moderate | VOLITIONRX LTD | Timothy I Still director | $25k 48,076 shares | +3% | |
| 29Weak | VNRXbuy VOLITIONRX LTD | Cameron John Reynolds President and CEO | $9,885 15,000 shares | +1% | |
| 46Moderate | VOLITIONRX LTD | Guy Archibald Innes director | $50k 78,125 shares | +9% | |
| 53Moderate | VOLITIONRX LTD | Cameron John Reynolds President and CEO | $50k 78,125 shares | +3% | |
| 41Moderate | VOLITIONRX LTD | Cameron John Reynolds President and CEO | $7,373 12,500 shares | +1% | |
| 36Weak | VOLITIONRX LTD | Guy Archibald Innes director | $11k 20,000 shares | +2% | |
| 44Moderate | VOLITIONRX LTD | Jacob Vincent Micallef Chief Scientific Officer | $22k 50,000 shares | +13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.